Gilead price target raised to $116 from $109 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...
Gilead upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Gilead (GILD) to Buy from Hold with a $108 price target Maximize Your Portfolio with Data Driven Insights:Leverage the power ...
Winter Is Coming on MSN18h
Watch the teaser trailer for the final season of The Handmaid's Tale on Hulu
The latest is for the sixth and final season of The Handmaid's Tale, Hulu's adaptation of Margaret Atwood's dystopian novel about a totalitarian government that forces the few remaining women capable ...
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Why Gilead (GILD) Is Advancing Today
Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and ...